BriaCell Therapeutics Corp.
Toronto Stock ExchangeTotal Valuation
BriaCell Therapeutics Corp. carries a market capitalization of 9.42M, placing it among publicly traded companies globally. Its enterprise value stands at -803,220.01, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.42M |
| Enterprise Value | -803,220.01 |
Share Statistics
BriaCell Therapeutics Corp. currently has 655,809.00 shares outstanding.
| Shares Outstanding | 655,809.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.26 |
| P/TBV Ratio | 1.03 |
| P/FCF Ratio | -0.50 |
| P/OCF Ratio | -0.50 |
Financial Position
BriaCell Therapeutics Corp. maintains a current ratio of 3.41, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.41 |
| Quick Ratio | 3.41 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -656.21 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -167.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
BriaCell Therapeutics Corp.'s stock has declined approximately -87.34177% over the past 52 weeks. The 50-day moving average sits at 4.79, while the 200-day moving average is 8.97.
| Beta (5Y) | N/A |
| 52-Week Price Change | -87.34177% |
| 50-Day Moving Average | 4.79 |
| 200-Day Moving Average | 8.97 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -24.27M, while operating income came in at -24.42M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -24.42M |
| Pretax Income | -19.64M |
| Net Income | -19.43M |
| EBITDA | -24.27M |
| EBIT | -24.42M |
| Earnings Per Share (EPS) | -71.80 |
Balance Sheet
Total book value stands at -9.64M, with working capital of 10.45M providing operational flexibility.
| Cash & Cash Equivalents | 12.46M |
| Total Debt | N/A |
| Net Debt | -12.46M |
| Equity (Book Value) | -9.64M |
| Book Value Per Share | -35.25 |
| Working Capital | 10.45M |
Cash Flow
BriaCell Therapeutics Corp. produced -24.07M in operating cash flow over the past twelve months.
| Operating Cash Flow | -24.07M |
| Capital Expenditures | N/A |
| Free Cash Flow | -24.07M |
| FCF Per Share | -88.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -299.31 |
| FCF Yield | -198.45 |
Stock Splits
BriaCell Therapeutics Corp.'s most recent stock split took place on August 25, 2025 with a 10:1 split ratio.
| Last Split Date | 8/25/2025 |
| Split Ratio | 10:1 |
Scores
BriaCell Therapeutics Corp. posts an Altman Z-Score of -11.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.24 |